The most recent readout with BI-1808 in combination with pembrolizumab in ovarian cancer, released yesterday evening, further strengthens our conviction in the combination. The preliminary PFS of 10.3 months is exceptional. BI-1808 + pembrolizumab increasingly looks like a promising new therapeutic option for multiple cancers.
LÄS MER
